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MLL rearrangements in humans lead to both acute myeloid leukemia (AML) and acute lymphoid leukemia
(ALL). While AML has been successfully produced inmice, modeling ALL has beenmore difficult. In this issue
ofCancer Cell, Wei et al. (2008) describe generation of AML, ALL, and biphenotypic leukemia bymanipulating
the cytokine milieu of human progenitor cells expressing MLL-AF9. They demonstrate that both multipotent
and lineage-restricted progenitors are targeted by MLL-AF9 fusion proteins and that Rac signaling is crucial
for survival. This study demonstrates the heterogeneity of MLL-AF9 leukemic stem cells and the importance
of the microenvironment in determining lineage outcome.Cancer Cell 13, June 2008 ª2008 Elsevier Inc. 465One of the most common chromosomal
breakpoint regions in human leukemias
occurs at chromosome 11q23. This re-
sults in balanced translocations that fuse
the mixed-lineage leukemia (MLL) gene,
in frame, to one of more than 50 partner
genes, resulting in expression of chimeric
oncogenic fusion proteins. MLL muta-
tions arise de novo and are also com-
monly found in therapy-related leukemia
following treatment with topoisomerase
inhibitors. MLL fusion proteins upregulate
expression of A cluster Hox genes and
Meis1, which are critical for transforma-
tion (Hess, 2004).
MLL rearrangements give rise to both
acute myeloid leukemia (AML) and acute
lymphoid leukemia (ALL). For unclear rea-
sons, some fusionpartners are associated
more commonly with AML than with ALL
and vice versa. The t(4;11) and t(11;19)
translocations that result in MLL-AF4 and
MLL-ENL are most frequently found in
ALL, while t(9;11) and t(6;11) that form
MLL-AF9 and MLL-AF6 fusions are the
most common genetic alterations of MLL
in AML. While these findings suggest that
the fusion partner provides an instructive
signal for lineage commitment of the
resulting leukemia (Daser and Rabbitts,
2004), MLL leukemias modeled in mice
using knockin technology or bonemarrow
retroviral transduction raise questions
about this model. For example, MLL-ENL
transduction and transplantation consis-
tently generates AML in mice despite be-
ing found equally in both AML and ALL in
humans (Lavau et al., 1997). In addition,
studies usingMLL-GAS7,whichproducesa biphenotypic leukemia, suggest that
leukemic stem cells (LSCs) (some prefer
the term leukemia-initiating cell) are multi-
potent (So et al., 2003). Recently, ALLwas
exclusively generated when MLL-ENL
was expressed in human hematopoietic
progenitor cells (HPCs) and transplanted
intomice (Barabe et al., 2007). These find-
ings raise a number of questions about
LSCs in MLL-associated leukemias. Are
LSCs heterogeneous? Do human and
mouse hematopoietic cells have intrinsic
differences that lead to different leuke-
mias? To what extent does the microenvi-
ronment affect leukemia phenotype? In
this issue of Cancer Cell, Mulloy and col-
leagues (Wei et al. 2008) experiment with
human cord blood transformed by MLL-
AF9 and provide important insights into
all of these questions.
Bone Marrow Microenvironment
Affects Leukemia Phenotype
To test the importance of the microenvi-
ronment, Wei et al. (2008) employed retro-
viral transduction of human CD34+ cord
blood and transplantation into three types
of mice: nonobese diabetic/severe com-
bined immunodeficient (NOD/SCID [NS]),
NS-b2M
/ (NS-B2M), and NS mice that
overexpress the human cytokines SCF,
GM-CSF, and IL-3 (NS-SGM3). Retroviral
transduction of MLL-AF9 readily immor-
talized CD34+ cells that could be cultured
to promote CD11b+CD13+CD14+CD15+
myelomonocytic cells. When cultured in
conditions promoting B cell differentia-
tion, lymphoid cells could be generated
expressing CD19 and CD10, demonstrat-ing the importance of culture conditions
for determining lineage outgrowth.
When MLL-AF9 cells from the myeloid
or lymphoid cultures were injected into
NS-SGM3 mice, aggressive myelomono-
cytic leukemia ensued. Strikingly, when
the same cells were injected into NS or
NS-B2Mmice, amix of AML, acuteB-lym-
phocytic leukemia (B-ALL), and acute bi-
phenotypic leukemia (ABL) resulted.While
B-ALL and ABL cells were present in the
injected mice, a distinct population of
AMLwasalsodetected, implying that sep-
arate LSCs had proliferated in the mice or
that a single LSC could generate both
AML and ALL.While it is likely that species
differences between human and mouse
progenitor cells play a role in disease out-
come, these data suggest that the cyto-
kine milieu of leukemic stem cells pro-
foundly affects their lineage commitment.
Heterogeneity of theMLL-AF9 LSCs
Previous studies of the frequency and ori-
gin of MLL fusion LSCs in diseased mice
suggest that both hematopoietic stem
cells (HSCs) and lineage-restricted pro-
genitors can function as LSCs when tar-
geted by MLL fusions. Furthermore, it ap-
pears that the fusion proteins are capable
of reinitiating a self-renewal program (Coz-
zio et al., 2003; Krivtsov et al., 2006; Som-
ervaille and Cleary, 2006). In contrast to
these previous studies, which utilized mu-
rine cells, Wei et al. (2008) tested whether
human MLL-AF9 LSCs are derived from
multipotent or lineage-restricted progeni-
tors. Cord blood was transduced with
MLL-AF9 and cultured under either
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tions. When injected into NS-
B2M mice, these produced
AML and ALL, respectively.
Intriguingly, B-ALL and AML
cells from separate diseased
transplant recipients were
found to be clonally related
as determined by Southern
blot analysis, demonstrating
the multipotency of the LSCs
and the potential for both
AML and ALL generation
from a single LSC. To deter-
mine the plasticity of more
committed progenitors and
whether they are also targeted
by MLL fusion proteins,
myeloid (CD19CD33+) and
lymphoid (CD19+CD33) cells
were isolated and cultured for
4 weeks. CD19+CD33 cells
were able to regenerate
CD19CD33+ cell types, and
clonal analysis demonstrated
that these cells originated
from the CD19+ LSCs.
CD19CD33+ cells did not
generate CD19+ cells in cell
culture but in some cases
produced both CD33+ AML
andCD19+ALL inmice. These
data highlight the heterogeneity of MLL-
AF9 LSCs, as both lineage-restricted and
multipotent progenitors are targeted by
MLL-AF9 and these cells retain at least
some differentiation capacity along the
myeloid and lymphoid lineage (Figure 1).
Rac Signaling Is Important
in MLL-AF9 AML
Although the cell signaling pathways in
MLL-associated leukemias are largely un-
defined, increased activity of Rac1 has re-
cently been reported in MLL-AF9 cells
(Somervaille and Cleary, 2006). Wei et al.
(2008) used shRNA and a Rac1-selective
small molecule to inhibit Rac1 function
and test the importance of this signaling
pathway in MLL-AF9 leukemic cells.
Treatment of MLL-AF9 cells with a Rac1
inhibitor resulted in cell-cycle arrest and
apoptosis, while treatment of control
cord blood or cells containing a different
fusion protein (AML-ETO) were not af-
fected. This effect was linked to regulation
of levels of antiapoptotic Bcl-xL, a down-
stream target of Rac1 signaling. Bcl-xL
was degraded in MLL-AF9 cells but re-
mained stable in cord blood or AML-
ETO cells. These experiments identify
the Rac1 signaling pathway as essential
and specifically required for growth of
MLL-AF9 cells and uncover a potential
therapeutic target for treatment of MLL
fusion leukemia.
The results presented by Wei et al.
(2008) strongly suggest a dynamic model
for determining leukemic lineage outcome
in whichMLL fusion proteins drive the sur-
vival and proliferation of target cells and
surrounding cytokines instruct cell lineage
decisions (Wei et al., 2008). This does not,
of course, exclude the possibility that fu-
sion partners also provide an instructive
signal or that translocation frequencies
vary between cell types because of the
expression levels at the involved loci.
The MLL-AF9 target cell appears to in-
clude both the stem and progenitor cell
compartments, and, given the regenera-
tion of myeloid cells from lymphoid cul-
tures, these target cells remain plastic
and receptive to environmental cues. Re-
cent data support greater plasticity within
the hematopoietic system (Iwasaki et al.,
2006). However, further com-
plexity is added by the recent
description of the effects of
gene dosage on leukemic
potential (Chen et al., 2008).
Mll-AF9 expressed at physio-
logic levels by knockin was
found to be expressed at
much lower levels than retro-
virally transduced MLL-AF9.
Furthermore, the fusion pro-
tein was expressed at higher
levels in stem cells than in
more differentiated progeni-
tor cells. This translated to
a significantly greater fre-
quency of transformable cells
in the stem cell compartment
compared to more differenti-
ated progenitors.
The current study provides
important insights, but a num-
ber of intriguing questions
about MLL cancer biology re-
main. Why are specific fusion
partners associated with par-
ticular lineages? It will be
interesting to test MLL-AF4
or MLL-ENL cells (commonly
associated with ALL) in the
NS-SGM3 mice that readily
formed AML. Can MLL fusion
proteins transform committed myeloid or
lymphoid cells at physiological expres-
sion levels? What is the basis for the se-
lective ‘‘addiction’’ of MLL fusion pro-
tein-transformed cells to Rac? And,
perhaps most importantly, is Rac signal-
ing the long sought-after ‘‘Achilles’ heel’’
that can be targeted for more selective
and effective therapies for leukemias
with MLL rearrangements?
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MicroRNAs (miRNAs) are noncoding
RNAs that regulate many cellular func-
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target genes through translational repres-
sion or direct mRNA degradation (Am-
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tions of the growing number of miRNAs
identified in the mammalian genome are
far from being completely characterized,
recent studies have indicated that de-
regulated expression of specific miRNAs
that modulate expression of oncogenes
and tumor suppressors is associated
with the development of malignancies,
and specific miRNA expression signa-
tures can be used to effectively classify
human tumors (Lu et al., 2005). Although
genome copy-number changes are asso-
ciated with altered levels of miRNA ex-
pression in various human malignancies
(Zhang et al., 2006), recent data suggest
that miRNA inactivation by epigenetic
mechanisms plays an important role
as well, and re-expression of certain
miRNAs by drugs that modulate epige-
netic changes can lead to downregulation
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More than 40 years ago, the Philadel-
phia (Ph) chromosome was identified by
Nowell and Hungerford. The Ph chromo-
some is a product of the t(9;22), which
fuses the Abelson kinase gene (ABL1)
from chromosome 9 with the breakpoint
cluster region (BCR) from chromosome
22 that expresses the BCR-ABL1 fusion
protein: a constitutively active tyrosine
kinase. The BCR-ABL1 fusion oncopro-
tein is a hallmark of chronic myelogenous
leukemia (CML) and is also present in
a fraction of B progenitor acute lympho-
blastic leukemia (ALL) cases that have
a particularly poor prognosis. Aberrant
expression of the wild-type ABL1 onco-
gene may also be associated with the de-
velopment of hematopoietic malignancies
including T cell lymphomas (Ren, 2005).
While the development of tyrosine kinase
inhibitors (TKIs) like imatinib mesylate
have revolutionized treatment of BCR-
ABL1-rearranged leukemias, it has be-
come increasingly clear in recent years
that TKI treatment alone will not be cura-
tive in many cases, particularly in acute
leukemias with BCR-ABL1 rearrange-
ment. Thus, further dissection of the
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regulatory networks that drive BCR-
ABL1-induced malignant transformation
may help to identify other novel therapeu-
tic approaches that complement TKI
treatment.
In this issue of Cancer Cell, a study by
Bueno et al. (2008) begins to elucidate
the role of silenced miRNA expression in
the regulation of BCR-ABL1-rearranged
leukemias and T cell lymphomas express-
ing ABL1. Using comparative genomic
hybridization (CGH) analysis of murine g
radiation-induced lymphomas, the au-
thors identify loss of heterozygosity of
a fragile 7 Mb chromosomal region on
murine chromosome 12, a region coding
for approximately 12% (52 miRNAs) of
the mammalian miRNAome known to
date. miRNA profiling revealed decreased
expression of one of the region’s miRNAs:
miR-203. Analysis of the miR-203 pro-
moter demonstrated that miR-203 is si-
lenced not only by genetic loss of one
allele but also epigenetically by promoter
CpG hypermethylation in the remaining
DNA copy (Figure 1). Next, the authors as-
sessed putative miR-203 targets and
identified the ABL1 tyrosine kinase
Cell 13, June 2008 ª2008 Elsevier Inc. 467
